Cynthia Chmielewski | CureTalks
Cynthia attended Rutgers University graduating with degrees in Psychology and Education. Upon graduation she secured her first teaching position and immediately fell in love with her chosen profession. Cynthia continued teaching for 28 years. Now retired, Cynthia, a myeloma survivor, is using her passion for education to teach a new group of "students" - myeloma patients and their caregivers. She is on the advisory boards of the Patient Empowerment Network, the Myeloma Crowd and the Philadelphia Multiple Myeloma Networking Group. Using social media to educate is her passion. Cynthia educates and advocates by tweeting at @MyelomaTeacher and sharing myeloma resources, educational opportunities and clinical trial information on her MyelomaTeacher Facebook page. Ms. Chmielewski is the co-founder of the #MMSM TweetChat and is also a regular panelist on CureTalks Podcast. Cynthia was an invited panelist and presented posters on using social media in hematology at the annual meetings of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR) and the European Bone Marrow Transplant (EBMT). More recently Cynthia joined the Patient Engagement team at Patient Power. Additionally, she consults on educational projects sponsored by the Myeloma Crowd. She enjoys serving as a voting member on the IRB at the University of Pennsylvania, a peer reviewer for the NCI’s DEA grants program and a patient advocate on the Myeloma Steering Committee of the National Cancer Institute (NCI) and ACCRU. Cynthia has also participated in the Department of Defense’s CMCRP grant reviews.
Related Talks
Beyond CAR-T: Re-engineering Cells into Life-saving Therapies
Our cells have the innate ability to protect us. The idea of using cells as medicine emerged with bone marrow transplants, and then…
Understanding the approach to integrative oncology
Research suggests that cancer patients are interested in using additional interventions that may help improve the efficacy of conventional cancer treatments, increase their…
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma.…
Covid-19 Vaccines – What Multiple Myeloma Patients Should Know?
Multiple myeloma patients are often immunosuppressed for months following treatments such as maintenance therapies, immunosuppressive drugs, hematopoietic cell transplant (HCT) and CAR-T therapies.…
Melflufen for Myeloma: A Deep Dive
The FDA recently granted priority review to a new drug application for melflufen (INN melphalan flufenamide), in combination with dexamethasone. Melflufen is intended…